Acumen Capital analyst Nick Corcoran has initiated coverage of NeuPath Health (NeuPath Health Stock Quote, Chart, News, Analysts, Financials TSXV:NPTH) with a “Buy” rating and a $0.95 target, saying the company is well positioned in a recession-resistant healthcare segment supported by rising demand for chronic pain treatment and an aging population. As reported by the […]
In an April 14 note, CIBC World Markets analyst Todd Coupland said he expects Celestica (Celestica Stock Quote, Chart, News, Analysts, Financials NYSE:CLS) to deliver “strong” first-quarter results and a solid full-year outlook when the company reports after the close on April 28. As reported by The Globe and Mail, Coupland maintained his “Outperformer” rating […]
Share
Tweet
Share
